Vitiligo pp 337-342 | Cite as

Editor’s Synthesis

  • Mauro PicardoEmail author
  • Alain Taïeb


We have summarized in Table 33.1 the current status of our understanding of vitiligo pathomechanisms. We have tried to divide it into major fields and levels of evidence. Clearly, in vivo evidence in human disease comes first. In vitro work, which relies on cultures, can be viewed more cautiously because of artifacts caused by culture conditions, even though appropriate controls are used. Some animal models are probably relevant, but definitive evidence is lacking.


  1. 1.
    Fitzpatrick TB, Breathnach AS. The epidermal melanin unit system. Dermatol Wochenschr. 1963;147:481–9.PubMedGoogle Scholar
  2. 2.
    Cario-André M, Pain C, Gauthier Y, et al. In vivo and in vitro evidence of dermal fibroblasts influence on human epidermal pigmentation. Pigment Cell Res. 2006;19:434–42.CrossRefGoogle Scholar
  3. 3.
    Yonetani S, Moriyama M, Nishigori C, et al. In vitro expansion of immature melanoblasts and their ability to repopulate melanocyte stem cells in the hair follicle. J Invest Dermatol. 2008;128:408–20.CrossRefGoogle Scholar
  4. 4.
    Picardo M. Lipid-mediated signalling and melanocyte function. Pigment Cell Melanoma Res. 2009;22:152–3.CrossRefGoogle Scholar
  5. 5.
    Saha B, Singh SK, Mallik S, et al. Sphingolipid-mediated restoration of Mitf expression and repigmentation in vivo in a mouse model of hair graying. Pigment Cell Melanoma Res. 2009;22:205–18.CrossRefGoogle Scholar
  6. 6.
    Taïeb A, Morice-Picard F, Jouary T, et al. Segmental vitiligo as the possible expression of cutaneous somatic mosaicism: implications for common non-segmental vitiligo. Pigment Cell Melanoma Res. 2008;21:646–52.CrossRefGoogle Scholar
  7. 7.
    Taieb A. Hypothesis: from epidermal barrier dysfunction to atopic disorders. Contact Dermatitis. 1999;41:177–80.CrossRefGoogle Scholar
  8. 8.
    Taieb A. NALP1 and the inflammasomes: challenging our perception of vitiligo and vitiligo-related autoimmune disorders. Pigment Cell Res. 2007;20:260–2.CrossRefGoogle Scholar
  9. 9.
    Gauthier Y. The importance of Koebner’s phenomenon in the induction of vitiligo vulgaris lesions. Eur J Dermatol. 1995;5:704–8.Google Scholar
  10. 10.
    Strömberg S, Björklund MG, Asplund A, et al. Transcriptional profiling of melanocytes from patients with vitiligo vulgaris. Pigment Cell Melanoma Res. 2008;21:162–71.CrossRefGoogle Scholar
  11. 11.
    Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9:139–50.CrossRefGoogle Scholar
  12. 12.
    Jin Y, Mailloux CM, Gowan K, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med. 2007;356:1216–25.CrossRefGoogle Scholar
  13. 13.
    Le Poole IC, Das PK, van den Wijngaard RM, et al. Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol. 1993;2:145–53.CrossRefGoogle Scholar
  14. 14.
    Happle R. Superimposed segmental manifestation of polygenic skin disorders. J Am Acad Dermatol. 2007;57:690–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Cutaneous Physiopathology and CIRMSan Gallicano Dermatological Institute, IRCCSRomeItaly
  2. 2.Service de DermatologieHôpital St André, CHU de BordeauxBordeauxFrance

Personalised recommendations